Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


The correlation of age-dependent reduction in sex hormones level and changes of cardiovascular system in men was shown recently. High prevalence and various clinical features of age-dependent hypogonadism demands to know diagnostics and management of patients with these disorders. Up to date data about changes of cardiovascular system related to androgen hormone levels reduction are presented. They should help in understanding of pathogenesis of many metabolic and clinical changes. Active attention to the problem of age-dependent hypogonadism, knowledge of organism functions in men with low androgen levels will help to optimize treatment, to avoid of mistakes in patient management, to reduce a risk of severe diseases and finally to improve quality of life and life expectancy of these patients.

About the Authors

G. G. Sharvadze
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990

D. G. Kurbatov
Endocrinology Research Centre
Russian Federation
Dmitriya Ulyanova ul. 11, Moscow, 117036

E. A. Poddubskaya
State Research Center for Preventive Medicine, I.M. Setchenov First Moscow State Medical University
Russian Federation

Petroverigsky per. 10, Moscow, 101990 

Chair of Evidence Based Medicine

Trubetskaya ul. 8, stroen. 1, Moscow, 119992

M. N. Mamedov
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


1. Шальнова С.А. Проблемылечения артериальной гипертонии. Кардиоваскулярная терапия и профилактика 2003; 2 (3): 17-21.

2. Suárez-García I., Sethi D., Hutchings A. Mortality due to injuries by place of occurrence in the European region: analysis of data quality in the WHO mortality database. Inj Prev 2009;15(4):275-7.

3. Goodman-Gruen D., Barrett-Connor E. Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care 2000;23(7):912-8.

4. Sullivan J.M. Practical aspects of preventing and managing atherosclerotic disease in postmenopausal women. Eur Heart J 1996;17 Suppl D:32-7.

5. Vermeulen A., Kaufman J.M., Goemaere S., van Pottelberg I. Estradiol in elderly men. Aging Male 2002;5(2):98–102.

6. Phillips G.B., Pinkernell B.H., Jing T.Y. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994;14(5):701-6.

7. Siemińska L., Wojciechowska C., Swietochowska E. et al. Serum free testosterone in men with coronary artery atherosclerosis. Med Sci Monit 2003;9(5):CR162-6.

8. Muller M., van den Beld A.W., Bots M.L. et al. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 2004;109(17):2074-9.

9. Svartberg J., von Mühlen D., Schirmer H. et al. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study. Eur J Endocrinol 2004;150(1):65-71.

10. Phillips G.B. Relationship between serum sex hormones and glucose, insulin and lipid abnormalities in men with myocardial infarction. Proc Natl Acad Sci U S A 1977;74(4): 1729-33.

11. Simon D., Charles M.A., Nahoul K. et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 1997;82(2):682-5.

12. Kaplan S.A., Meehan A.G., Shah A. J Urol 2006;176(4 Pt 1):1524-7.

13. Верткин А.Л., Аринина Е.Н., Колосова Е.С. и др. Гендерные подходы к лечению сердечно-сосудистой патологии: мужчина в центре внимания. РМЖ 2008;16 (спец- выпуск):17-21.

14. Petak S.M., NankinH.R., Spark R.F. et al. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients – 2002 update. Endocr Pract 2002;8(6):440-56.

15. Jockenhovel F .Testosterone supplementation: What and how to give Aging Male 2003;6(3):200-6.

16. Morales A., Lunenfeld B. International Society for the Study of the Aging Male. Investigation, treatment and monitoring of late onset hypogonadism of males. Official recommendations of IS-SAM. International Society for the Study of the Aging Male. Aging Male 2002;5(2):74-86.

17. Калинченко С.Ю.,Козлов Г.И., Вадов В.В.Клиника, диагностика и лечение эректильной дисфункции, обусловленной возрастным дефицитом андрогенов (синдрома PADAM) у мужчин. Сексология и сексопатология 2003;(5):2-4.

18. Araujo A.B., O'Donnell A.B., Brambilla D.J. et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts MaleAging Study. J Clin Endocrinol Metab 2004;89(12):5920-6.

19. Mulligan T., Frick M.F., Zuraw Q.C. et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006;60(7):762-9.

20. Мамедов М.Н. Эректильная дисфункция, андрогенодефицитное состояние и сердечно-сосудистые заболевания: комплексный подход к проблемам мужского здоровья. Научно-методическое пособие. М.; 2008.

21. Аляев Ю.Г., Григорян В.А., Чалый М.Е. и др. Возрастной андрогенный дефицит и современные методыего медикаментозной коррекции. Врачебное сословие 2006;(5- 6):50-3.

22. Зилов А.В., Шейлор И.М., Гусова А.А. Возрастной гипогонадизм: особенности диагностики, клиники и лечения. Фарматека 2007;(11):38-43.

23. Лоран О.Б., Верткин А.Л., Алексанян Л.А. и др. Возрастной андрогенный дефицит в общесоматической практике: причины возникновения, клиника, диагностика и лечение. Методические рекомендации. М.; 2007.

24. Rosen R.C., Riley A., Wagner G. et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49(6):822- 30.

25. Калинченко С.Ю. Современный взгляд на проблему возрастного андрогенного дефицита у мужчин. Лечащий врач 2009;(1):10-3.

26. Winters S.J. Current status of testosterone replacement therapy in men. Arch Fam Med 1999;8(3):257-63.

27. Верткин А.Л., Моргунов Л.Ю., Аринина Е.Н., Колосова Е.С. Дефицит тестостерона и соматическая патология. Лечащий врач 2006;(10):12-6.

28. Schubert M., Minnemann T., HüblerD. et al. Intramusculartestosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004;89(11):5429-34.

29. Zitzmann M., Erren M., Kamischke A. et al. Endogenous progesterone and the exogenous progestin norethisterone enanthate are associated with a proinflammatory profile in healthy men. J Clin Endocrinol Metab 2005;90(12):6603-8.

30. Heufelder A.E., Saad F., Bunck M.C., Gooren L. Fifty-two-week treatment with diet and exercise plus transdermaltestosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009;30(6):726-33.

31. Malkin С.J., Pugh P.J., Morris P.D. et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004;90(8):871-6.

32. Pugh PJ, Jones RD, West JN et al. Testosterone treatment for men with chronic heart failure. Heart 2004;90(4):446-7.

33. Аметов А.С., Верткин А.Л., Моргунов Л.Ю. и др. Возможности коррекции кардиоваскулярной патологии у мужчин с возрастным дефицитом андрогенов. Тер архив 2007; 79(10): 50-53.

34. Мамедов М.Н., Чепурина Н.А. Определение суммарного сердечно-сосудистого рис- ка в клинической практике. Руководство для врачей. М.; 2008.

For citation:

Sharvadze G.G., Kurbatov D.G., Poddubskaya E.A., Mamedov M.N. HYPOANDROGEN CONDITION AND CARDIOVASCULAR DISEASES: ACTUAL QUESTIONS OF COMORBIDITY IN CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology. 2010;6(4):532-538. (In Russ.)

Views: 444

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)